The US company’s corona vaccine has already been approved in the EU.
(Photo: AFP/Getty Images)
Frankfurt Covid vaccines have brought huge commercial success to Pfizer, Biontech and Moderna. On the other hand, the situation for laggards in vaccine development such as Novavax and Valneva is far more difficult and characterized by great uncertainty. The two companies are using alternative technologies to compete against the now dominant mRNA vaccines from Pfizer/Biontech and Moderna.
The shares of the two companies always cause a stir on the stock exchange. At Valneva, for example, the price rose by up to 20 percent in mid-April after the French company received approval in Great Britain for its Covid vaccine – the first in a larger western market.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue